Roundtable: Quality and Polyfunctionality in Cell Therapy Development can Broaden Therapeutic Options

Sit in with industry leaders to learn why there is a need to define best practices and improve quality management in Immunotherapy.

This expert panel discussion was featured in the GEN Supplement: Immunotherapy Pipeline.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Differences in development of cell therapies vs traditional antibody therapeutics
Gap in the current standard methods of evaluating the quality, potency, and durability of cell therapy CAR T-cell products
Opportunity for future cell therapy advancements
Evaluation of CAR T-cell therapies preclinically and during bioprocessing
A Deeper Look

More about this

What Influences the Therapy’s Results?

Possibilities include the distinctive characteristics of the individual patient’s disease, the quality of the T cells taken from the patient and used to manufacture the product, the quality of the assays used to predict individual efficacy and toxicity responses, and the manufacturing process.

GEN talked to five leading researchers in the field to get their input on the status of the field, the outstanding challenges, and the tools and techniques needed to help complete the circle of understanding to and advance the field.

Download this eBook to read what they had to say.

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the